Conclusion
CRPC, mCRPC, prostate cancer
DNA DAMAGE, PROSTATE CANCER
In this small series, one-third of mCRPC patients responded to platinum–based chemotherapy. Peripheral blood biomarker measurement is feasible in mCRPC, though the biomarkers we investigated were not associated with platinum response. Other biomarkers, such as DNA damage repair mutations, should be evaluated.Repeat biopsies are uncommon in metastatic castration–resistant prostate cancer (CRPC), limiting the feasibility of tissue–based biomarkers. This article evaluates the feasibility and utility of blood–based biomarkers to identify platinum–sensitive mCRPC.